DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 1, 2010.

Dated: August 13, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–21745 Filed 8–31–10; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 5, 2010, Austin Pharma LLC., 811 Paloma Drive, Suite C, Round Rock, Texas 78665– 2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Marihuana (7360) Tetrahydrocannabinols (7370) Alphamethadol (9605) Nabilone (7379) Methadone (9250) Methadone (9250) Levo-alphacetylmethadol (9648) Alfentanil (9737) Remifentanil (9739) Sufentanil (9740) Fentanyl (9801)	

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 1, 2010.

Dated: August 2, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator/Deputy Chief of Operation, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–21785 Filed 8–31–10; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 15, 2010, American Radiolabeled Chemicals, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010).	1
Ibogaine (7260)	1
Lysergic acid diethylamide (7315)	i
Tetrahydrocannabinols (7370)	li
Dimethyltryptamine (7435)	1
1-[1-(2-	1
Thienyl)cyclohexyl]piperidine (7470).	
Dihydromorphine (9145)	1
Normorphine (9313)	1
Amphetamine (1100)	11
Methamphetamine (1105)	11
Amobarbital (2125)	Ш
Phencyclidine (7471)	П
Phenylacetone (8501)	II
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Ecgonine (9180)	II
Hydrocodone (9193)	II
Meperidine (9230)	II
Metazocine (9240)	II
Dextropropoxyphene, bulk (non- dosage forms) (9273).	II
Morphine (9300)	l II
Oripavine (9330)	ü
Thebaine (9333)	ü
Oxymorphone (9652)	lii
Phenazocine (9715)	ii
Fentanyl (9801)	II
, (,	

The company plans to manufacture small quantities of the listed controlled

substances as radiolabeled compounds for biochemical research.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 1, 2010.

Dated: August 3, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010–21784 Filed 8–31–10; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 11, 2010, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Dihydromorphine (9145) Amphetamine (1100) Methamphetamine (1105) Amobarbital (2125) Pentobarbital (2270) Secobarbital (2315) Phenylacetone (8501) Cocaine (9041) Codeine (9050) Dihydrocodeine (9120) Oxycodone (9143) Hydromorphone (9150) Diphenoxylate (9170) Ecgonine (9180) Hydrocodone (9193) Meperidine (9230) Methadone (9250)	Schedule
Methadone (9250)	II .

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.